Radiopharm shares surge 21.79% premarket after successful general meeting approves all proposed resolutions.

Radiopharm Theranostics surged 21.79% in premarket trading following the announcement of a successful General Meeting on December 3, 2025, where all proposed resolutions were approved. The company attributed the outcome to strong shareholder support, signaling confidence in its strategic direction. The approval of key resolutions typically enhances corporate governance and operational clarity, which investors interpreted as a positive catalyst for future growth. The stock’s significant premarket increase directly correlates with the news, reflecting market optimism over the firm’s governance developments and potential execution of approved initiatives.